Thousand Oaks

Thousand Oaks Biopharmaceuticals is an integrated CMC enterprise specializing in cell culture media and CDMO services. It owns Thousand Oaks Biopharmaceuticals Co. Ltd. (Nantong), Shanghai Thousand Oaks Biopharmaceuticals Co., Ltd., Jianshun Biotechnology (Nantong) Co., Ltd., Gansu Jianshun Biotechnology Co., Ltd., Shanghai Jianshibai Biotechnology Co., Ltd., and THOUSAND OAKS BIOPHARMACEUTICALS, INC. (USA). The company has production bases or R&D laboratories in Nantong, Jiangsu; Shanghai; Lanzhou, Gansu; and the San Francisco Bay Area, California, USA. Thousand Oaks Biopharmaceuticals aims to become a leading enterprise in China's biopharmaceutical industry by integrating raw materials, consumables, pharmaceutical equipment, technical services, and contract manufacturing. Focused on biopharmaceutical production-related businesses (CMC Biomanufacturing), it provides customers with one-stop services covering "R&D - process - production - logistics - technical support - after-sales service." Thousand Oaks Biopharmaceuticals boasts an international operational and technical team with years of experience in biopharmaceutical processes and industrialization. The company offers advanced CDMO services and has successfully passed quality audits based on China's NMPA, the U.S. FDA, and the EU EMA standards multiple times. Thousand Oaks Biopharmaceuticals has a production capacity of 2,000L batch culture and 500L perfusion culture. Its formulation production workshop is equipped with capabilities for vial filling/lyophilization and pre-filled syringe/cartridge filling, enabling simultaneous production services for multiple product types for both domestic and international clients.